Study supports IM tranexamic acid as IV alternative in dogs

A new AJVR study reports that intramuscular tranexamic acid reaches lower peak plasma concentrations than intravenous dosing in healthy dogs, while delivering comparable overall systemic absorption. The study used a randomized crossover design in six healthy client-owned dogs given 20 mg/kg TXA by both routes, with a six-week washout between treatments. In practical terms, the paper points to IM administration as a potentially workable fallback when rapid IV access isn’t available. (pubmed.ncbi.nlm.nih.gov)

That question matters because TXA has had an uneven evidence base in dogs. A 2018 AJVR study found that TXA improved clot strength and reduced fibrinolysis in an in vitro hyperfibrinolysis model using blood from healthy dogs, and that plasma concentrations after 20 mg/kg IV briefly exceeded levels thought to fully inhibit fibrinolysis. But veterinary clinicians still lack clear consensus on optimal dosing, route, target concentrations, and which canine patients are most likely to benefit. Reviews aimed at practitioners have framed TXA as promising, but still short on definitive clinical protocols. (pubmed.ncbi.nlm.nih.gov)

The new study adds route-specific pharmacokinetic detail. Based on the abstracted report, IM administration led to a lower Cmax than IV administration, which is expected, but systemic absorption was comparable, suggesting the drug is still substantially bioavailable when given intramuscularly. That distinction could matter clinically: lower peaks may reduce some concentration-related effects, while similar total exposure may preserve antifibrinolytic potential over time. A similar pattern has been reported in human crossover research, where IM TXA reached therapeutic levels quickly but with lower peak concentrations than IV dosing. (pubmed.ncbi.nlm.nih.gov)

There’s also a safety and tolerability angle behind the route question. Earlier canine studies have documented vomiting with IV TXA, especially at higher or faster-administered doses. In one AJVR study evaluating TXA as an emetic, IV administration reliably induced vomiting in many dogs at escalating doses, underscoring that route and administration strategy can strongly shape the clinical experience. Another study in healthy dogs found transient vomiting after IV boluses in early cases, after which investigators slowed and reduced the bolus dose. (pubmed.ncbi.nlm.nih.gov)

Industry or expert reaction specifically to this paper was limited in publicly indexed sources at the time of review. Still, the broader professional conversation has already been moving toward route flexibility. Educational reviews for small animal clinicians have noted that antifibrinolytics may be considered in trauma, perioperative bleeding, spontaneous hemoperitoneum, and selected coagulopathies, while also warning that patient selection and adverse-effect monitoring matter. That makes this pharmacokinetic paper useful as a building block, even without direct evidence yet that IM TXA changes outcomes. (todaysveterinarypractice.com)

Why it matters: For veterinary teams, this study is best read as operational evidence, not practice-changing proof of efficacy. In emergency and critical care, a route that doesn’t depend on immediate catheter placement can be attractive, especially in unstable patients, field settings, or busy ER workflows. But pharmacokinetic comparability is not the same as clinical equivalence. Existing canine clinical studies have not consistently shown clear benefit from TXA in every bleeding scenario; for example, retrospective work in surgically treated hemoperitoneum did not find reduced transfusion needs or postoperative bleeding, and a 2024 greyhound study did not show a reduction in postoperative hemorrhage with prophylactic TXA. (pubmed.ncbi.nlm.nih.gov)

That leaves several open questions. Healthy-dog PK data don’t fully predict what happens in shock, active hemorrhage, altered perfusion states, or coagulopathic disease. Clinicians still need better evidence on whether IM TXA reaches effective concentrations fast enough in unstable dogs, whether it reduces vomiting or other adverse effects compared with IV use, and which cases actually benefit. The human literature has helped normalize IM TXA as a contingency route in settings where IV access is delayed, but veterinary medicine still needs direct clinical-outcome studies before the route can be recommended broadly. (pubmed.ncbi.nlm.nih.gov)

What to watch: Watch for full publication details, any follow-on CSU or ECC commentary, and, more importantly, prospective trials in bleeding or trauma patients that tie IM TXA exposure to transfusion needs, hemostatic endpoints, adverse effects, and survival. (2024acvimforum.eventscribe.net)